tbuckley/cabot-search huggingface dataset:
Truth-conduciveness as the primary epistemic justification of normative systems of reasoning
Authors: Gerhard Schurz
Journal: Behavioral and Brain Sciences (2011)

Abstract Although I agree with Elqayam &amp; Evans' (E&amp;E's) criticisms of is-ought and ought-is fallacies, I criticize their rejection of normativism on two grounds: (1) Contrary to E&amp;E's assumption, not every normative system of reasoning consists of formal rules. (2) E&amp;E assume that norms of reasoning are grounded on intuition or authority, whereas in contemporary epistemology they have to be justified, primarily by their truth-conduciveness.
FRI0299 Methotrexate: A therapeutic option in symptomatic knee osteoarthritis: Randomized placebo-controlled trial
Authors: S. Abou-Raya, A. Abou-Raya, N. Sallam
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Osteoarthritis (OA) is a common disabling condition, for which no effective therapy currently exists. Synovitis is commonly demonstrated in knee OA imaging. Synovial inflammation due to the release of prostaglandins and cytokines is an important cause of pain. Methotrexate (MTX) helps to decrease synovitis in many inflammatory joint diseases, particularly rheumatoid arthritis. <h3>Objectives</h3> To assess the efficacy of MTX in decreasing pain and inflammation in symptomatic knee OA. <h3>Methods</h3> Eighty-eight patients with American College of Rheumatology (ACR) clinical and radiographic criteria of primary knee OA with knee pain, [&gt;4 on the 24-hour average pain severity scale (0-10) using mean of daily ratings from week preceding randomization] for &gt;14 days/month during 3 consecutive months preceding enrollment were included in this randomized double-blind placebo-controlled trial. Exclusion criteria included any other inflammatory conditions, hepatic and renal insufficiency. Patients meeting the eligibility criteria were randomized in a 1:1 ratio to receive either 25mg/week oral MTX (n=44) or placebo (n=44) together with their usual therapy provided the dosages were kept constant for 16 weeks. The primary outcome measure was pain reduction and secondary outcome measures included improvements in physical function scores. Pain was assessed using the Visual Analogue pain Scale, (VAS, 0-100 mm). Functional assessment was performed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Activities of daily living (ADL) scores. Alterations in dosage of analgesic/NSAID drugs used were recorded. Safety and tolerability were also assessed. Synovitis was detected by ultrasound imaging at baseline and at the end of the study. <h3>Results</h3> There was a statistically significant reduction in pain in the MTX group compared to the placebo group, p=0.007. In addition, there was a significant improvement in WOMAC and ADL scores at 16 weeks in the intervention group versus the placebo group as well as statistically significant improvement in patient and physician assessment of pain. NSAID use was significantly less in the MTX versus the placebo group, p=0.055. Statistically significant improvement in synovitis, as detected by ultrasound, occurred in the MTX group compared to the placebo group at 16 weeks. No serious side effects were reported. <h3>Conclusions</h3> MTX significantly reduced pain and improved synovitis. In addition, there was a significant improvement in physical function. MTX may be a therapeutic option in the treatment of pain and inflammation related to OA. However, further large scale longitudinal studies are needed to confirm these results. <h3>Disclosure of Interest</h3> None Declared
THU0366 Does being a hepatitis B virus carrier decrease applying to hospital in patients with rheumatoid arthritis and ankylosing spondylitis?:
Authors: O. Karadag, N. Yilmaz, A. Yazici, B. Kisacik, S. Yilmaz, T. Kasifoglu, U. Kalyoncu, H. Temiz, B. Baysal, A.M. Onat
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Immunosupressive therapy, especially tumor necrosis factor-α (TNF-α) inhibitors can induce viral reactivation and potentially fatal liver failure in patients with concurrent Hepatitis B virus (HBV) or Hepatitis C virus (HCV) infection. But the prevalence of HBV and HCV infections could differ according to geographic regions. Although it is suspected as the prevalance of HBV and HCV in patients with rheumatoid artritis (RA) and ankylosing spondilitis (AS) in not different from general population, multicenter countrywide studies are required to support this idea <h3>Objectives</h3> The aim of this study was to investigate the prevalence of HBsAg and Anti HCV seropositivity in RA and AS patients. <h3>Methods</h3> Totally 1514 (F:M=1176/338) RA and 854 (F:M=388/466) AS consecutive patients who were fulfilling ACR 1987 RA and ASAS-EULAR 2009 Spondyloarthropathies criteria and being regularly followed in Rheumatology outpatient clinic from the six different geographic areas of Turkey were recruited in this study. The prevalence of HBsAg and Anti HCV were retrospectively investigated and compared with general population data from "Turkish Hepatology Society" prevalence study that included 5465 healthy subjects. <h3>Results</h3> The mean age was 48.7±13.9 years in RA and 36.9±10.8 years in AS patients. The mean disease duration was 6.4±6.1 and 6.3±5.9 years, respectively. HBsAg prevalance was lower both RA and AS patients than general population [33 (2.2%), 25 (2.9%) and 218 (3.99%), respectively; p&lt;0.01]. On the other hand Anti HCV prevalence was not different among the groups [15 (1%), 8 (0.9%) and 52 (0.95%), respectively; p&gt;0.05] (see Table 1). HBsAg and Anti HCV seropositivity were higher in female than male patients in RA group (HBsAg; 3.9% vs 1.7, p=0.01 and Anti HCV; 1.3% vs 0%, respectively, p=0.03). However, no difference was observed in HBsAg and Anti HCV results between gender in the AS group. (HbsAg; 3.5% vs 2.6% and Anti HCV; %0.8 vs %1.1, respectively p&gt;0.05). <h3>Conclusions</h3> Prevalence of HBsAg seropositivity in patients with RA and AS is lower than general population. Further studies are required about this low prevalence. Being a HBV carrier might decrease applying to hospital in patients with RA and AS. <h3>Disclosure of Interest</h3> None Declared
Abstract LB-133: A novel tumor suppressor role for sirt1 inhibiting mitophagy in prostate mouse tissue.
Authors: Gabriele Di Sante, Liping Wang, Chenguang Wang, Sara Bisetto, Mathew C Casimiro, Michael Powell, Michael McBurney, Richard Pestell
Journal: Cancer Research (2013)

Abstract Introduction. Sirtuin family consists of NAD+-dependent class III histone deacetylases (HDACs). Sirtuin family members (SIRT1-SIRT7) were shown to regulate a variety of physiopathological process, including aging, cellular proliferation, metabolism, and autophagy. Prior studies report SIRT1 as either an oncogene or a tumor suppressor depending upon the cell type and system. However, a reduced expression of SIRT1 in prostate cancer has been reported, supporting the view of SIRT1 as a tumor suppressor. Deregulated intracellular reactive oxygen species (ROS) production induces oxidative stress and damage of nucleic acids, proteins and lipids and may contribute to tumorigenesis. Herein, we provide in vivo support for SIRT1 as a tumor suppressor in prostate cancer. The mechanism appears to involve SIRT1-mediated inhibition of A) mitochondrial ROS production and B) mitophagy. Materials and methods. 7 month old Sirt1 transgenic mice were used. To investigate the molecular mechanisms through which SIRT1 regulate mitochondrial ROS production and mitophagy process, 3T3 cells wild type (Sirt1+/+) and SIRT1 knockout (Sirt1-/-) were used. Results. Our clinical and experimental data show a decrease in both SIRT1 expression associated with reduced patient survival probability. A histological evaluation of the H&amp;E performed on both Sirt1+/+ and Sirt1-/- mouse prostate tissues demonstrates that there is a focal atypical intraductal proliferation in prostatic glands of the Sirt1-/- mice, compatible with high grade prostatic intraductal neoplasia (HGPIN). The IHC and relative quantitation of the mouse prostate tissues with Ki67 and AMACR, which are a proliferative and PIN marker respectively, showed an increase of both markers in Sirt1-/- mouse prostate tissue. Preliminary data generated from Sirt1+/+ and Sirt1-/- 3T3 cells suggest that SIRT has a key role in maintaining the mitochondrial healthy status regulating ROS. Sirt1-/- cells undergo a higher oxidative stress, which can lead to cellular damage. We also found mitophagy markers; Beclin1, Bnip3l and LC3 to be overexpressed in Sirt1-/- mouse prostate tissues. Conclusion and future prospects. These studies suggest SIRT1 inhibits PIN in vivo. The molecular mechanism through which SIRT1 works in a tumor suppressor way is still unknown. We propose a loss of SIRT1 expression may alter the oxidative environment, thereby promoting PIN. Citation Format: Gabriele Di Sante, Liping Wang, Chenguang Wang, Sara Bisetto, Mathew C Casimiro, Michael Powell, Michael McBurney, Richard Pestell. A novel tumor suppressor role for sirt1 inhibiting mitophagy in prostate mouse tissue. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr LB-133. doi:10.1158/1538-7445.AM2013-LB-133
EVALUATING CHANGE OF SYSTOLIC FUNCTION AFTER REVASCULARIZATION IN PATIENTS WITH MULTI VESSEL CORONARY ARTERY DISEASE, SEVERELY REDUCED LEFT VENTRICULAR SYSTOLIC FUNCTION AND NO SCAR ON CMR IMAGING
Authors: Alexander Ivanov, James Yossef, Ambreen Mohamed, Joshua Socolow, Iossif Gulkarov, Berhane Worku, Anthony Tortolani, Pairoj Chattranukulchai, Terrence Sacchi, Robert Biederman, John Grizzard, Mohamad Ghosn, Igor Klem, John Heitner
Journal: Journal of the American College of Cardiology (2015)
TRATAMIENTO DE LA DISRUPCIÓN DUCTAL PANCREÁTICA MEDIANTE PRÓTESIS TRANSPAPILAR: ANÁLISIS DE LOS FACTORES ASOCIADOS CON EL ÉXITO TERAPÉUTICO
Authors: JJ Vila, D Ruiz-Clavijo, B González De La Higuera, E Valdivielso, C Prieto, MA Casi, F Bolado, J Urman, I Fernández-Urién, FJ Jiménez
Journal: Endoscopy (2014)

Introducción: El tratamiento de la disrupción ductal pancreática (DDP) mediante prótesis pancreáticas transpapilares (PT) resuelve la DDP en el 44 – 92% de los casos, especialmente si la PT puentea la DDP, lo cual es técnicamente muy complejo.
METABOLIC SYNDROME IS ACCOMPANIED BY INCREASED SYMPATHETIC NERVOUS SYSTEM ACTIVITY AND ARTERIAL STIFFNESS IN RESISTANT HYPERTENSION
Authors: Konstantinos P. Tsioufis, Kyriakos Dimitriadis, Evaggelia Koutra, Alexandros Kasiakogias, Athanasios Kordalis, Dimitris Tsiachris, Theodoros Kalos, Ioannis Andrikou, Dimitris Flessas, Dimitris Tousoulis
Journal: Journal of the American College of Cardiology (2015)
The Cutaneous Manifestations of Systemic Diseases
Authors: Anthony C. Cipollaro, Philip Schwartz
Journal: New England Journal of Medicine (1954)

IT is becoming generally accepted that many cutaneous abnormalities are symptomatic of general diseases and, therefore, that a disease may have in common various manifestations detectable in various organs of the body. However, there are many severe generalized and universal eruptions, some of which terminate fatally, such as pemphigus, which in the present state of knowledge appears to be entirely of cutaneous origin with no apparent organic abnormalities of other organs. The presence of cutaneous changes in systemic diseases has been particularly emphasized in recent years with the discovery of new findings in collagen diseases. The work of Libman and . . .
Abstract 4760: Evaluation of the progesterone receptor status using three different antibodies: A comparison by Allred score system.
Authors: Klesia P. Madeira, Renata Daltoe, Alex Carvalho, Lucas Rezende, Ian Silva, Leticia Rangel
Journal: Cancer Research (2013)

Abstract Abstract: Breast cancer (BC) hormonal receptors (progesterone, PgR and estrogen) status is assessed by immunohistochemistry (IHC), a specific, sensitive, and accessible method that guide BC treatment. We evaluated PgR expression in 53 BC cases using 3 anti-PgR antibodies (AB): monoclonal (SP42 and RP636) and polyclonal ab62621. Methods: Primary BC cases (with signed informed consent) were used to generate tissue microarray platforms, where PgR expression was accessed by IHC and evaluated by the Allred score. Categorical and quantitative data are shown in percentage and mean, respectively. Concordance (CON) and correlation among ABs were analyzed by Kappa factor (K), Spearman's correlation coefficient (ρ) or intraclass correlation coefficient. Staining patterns of each AB were compared by paired T-Test. Findings: We noted poor CON and K between ab62621 vs SP42 (CON=64.1%; K=0.247), and ab62621 vs RP636 (CON=62.3%; K=0.204), but higher CON between SP42 vs RP636 (CON 90.6%; K =0.738). Data were corroborated by Mc Nemar statistical test (p=0.019, p=0.014 and p&amp;gt;0.05, respectively). Regarding staining intensity among PgR+ samples, we found higher proportion of weak staining and lower IS for ab62621 (48.3%; mean IS=1.6), when compared to SP42 (20.0%, mean IS=2.1, T-test p&amp;lt;0.01) and RP636 (2.3, 21.9%, T-test p&amp;lt;0.01). Within the entire sample, similar results were observed following ρ: SP42 vs RP636 (ρ=0.8103); ab62621 vs SP42 (ρ=0.3524); ab62621 vs RP636 (ρ=0.4075). As for proportion of stained cells and PS, among PgR+ samples, the mean values for ab62621 (75.4%; 4.8) were significantly higher than those of SP42 (56.3%, 4.3; T-test p&amp;lt;0.01) and RP636 (60.1%; 4.2; T-test p&amp;lt;0.01). Similar data were found after analyzing PS for the entire sample: SP42 vs RP636 (ρ=0.8588); SP42 vs ab62621(ρ=0.4832); RP636 vs ab62621(ρ=0.4050). Interpretation: Our data indicate that anti-PgR monoclonal ABs, RP636 and SP42, are, unlike ab62621, equally suitable to test BC PgR status by IHC due to their higher accuracy. Therefore, we suggest their clinical use during BC diagnosis; thus, enabling more precise therapeutic decisions to treat BC. Citation Format: Klesia P. Madeira, Renata Daltoe, Alex Carvalho, Lucas Rezende, Ian Silva, Leticia Rangel. Evaluation of the progesterone receptor status using three different antibodies: A comparison by Allred score system. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4760. doi:10.1158/1538-7445.AM2013-4760 Note: This abstract was not presented at the AACR Annual Meeting 2013 because the presenter was unable to attend.
CARDIAC CATHETERIZATION IN CANCER PATIENTS WITH THROMBOCYTOPENIA: 4-YEAR EXPERIENCE FROM A HIGH VOLUME CANCER CENTER CARDIAC CATHETERIZATION LABORATORY
Authors: Cezar Iliescu, Syed Yusuf, Gloria Iliescu, Pimprapa Vejpongsa, Jean-Bernard Durand, Elie Mouhayar, Mehmet Cilingiroglu, Konstantinos Marmagkiolis
Journal: Journal of the American College of Cardiology (2015)
AB0865 Factors Which Influence the Effect of Analgesic Therapy
Authors: A. Karateev, T. Tsapina
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Effective of pain relief is an important element of the treatment of rheumatic diseases. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most popular class of analgesics. To predict their effect, depending on the particular clinical situation is an actual problem. <h3>Objectives</h3> To evaluate the dependence of the efficiency of ketoprofen lysine salt (KLS) on a number of clinical factors, as well as the determination of the relationship between the level of analgesia and the subjective evaluation of the effectiveness of this drug. <h3>Methods</h3> There are data of open 2-week observational study KLS outpatients with muscular-skeletal disorders, which suffered from severe pain. The study group included 4609 patients, the most part with back pain and OA, 64.4% of women and 35.6% of male, age 50.2±12.8 years. Physicians could prescribe at their own discretion different forms of KLS (intramuscular (i.m.), per os, topical) or their combinations. Treatment efficacy was assessed by the dynamics of pain (100- mm VAS) and satisfaction of patients (scale of 1-5 points, where "1" - no effect, and "5" - great effect). <h3>Results</h3> Intensity of pain decreased from 67.93±15.63 to 15.96±13.48 mm, the dynamics of pain was -52.2±18.5 mm VAS. Most patients (87.1%) reported "excellent" and "good" effect of KLS. There was a strong correlation between satisfaction with care and the dynamics of pain. Thus, the difference between the valuation of reducing pain "1" and "2" was 14.3 (2.9-25.7), p=0.014; "2" and "3" - 11.1 (6.7-15.5), p&lt;0.001; "3" and "4" - 8.5 ( 6.9-9.9), p&lt;0.001; "4" and "5" - 14.2 (13.3-15.3) mm VAS, p&lt;0.001. The safety of KLS was good: significant side effects were found in 1.3%. Was evaluated treatment satisfaction upon factors such as sex, age&gt;60 years old, diagnosis of OA, applying KLS i.m., prior NSAIDs, use of muscle relaxants, and the absence of side effects. Gender, age, and prior use of NSAIDs did not affect satisfaction. The diagnosis of OA was associated with a significant reduction effect (OR, 95% CI) - 0.702 (0.645-0.764); use of i.m. injection, taking muscle relaxants, and absence of complications with increasing effect: 1.12 (1.51-2.77), 1.1 (1.06-1.11) and 2.05 (1.51-2.77). <h3>Conclusions</h3> KLS is effective and relatively safe agent for the treatment of musculoskeletal pain. The difference in subjective valuation of KLS efficacy (for example, between "good" and "excellent"), identifying patients, on average, was associated with reduced pain by 12.0 (7.9-16) mm VAS. Efficacy of KLS was lower in patients with OA. Initiation of treatment with i.m. KLS, the combination with muscle relaxants and absence of complications increases the effectiveness of treatment. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3808
Beneficial Effects of High Dietary Fiber Intake in Patients with Type 2 Diabetes Mellitus
Authors: Manisha Chandalia, Abhimanyu Garg, Dieter Lutjohann, Klaus von Bergmann, Scott M. Grundy, Linda J. Brinkley
Journal: New England Journal of Medicine (2000)

The effect of increasing the intake of dietary fiber on glycemic control in patients with type 2 diabetes mellitus is controversial.
BRAIN TUMOR CARE THROUGH THE PATIENT'S EYES -- THE VALUE OF A COMPREHENSIVE BRAIN TUMOR CENTER
Authors: M. L. Rosenblum, A. Robin, T. Walbert, T. Mikkelsen, S. Kalkanis, M. Rosenblum
Journal: Neuro-Oncology (2014)

BACKGROUND: (blind field). METHODS: Surveys of patients, caregivers and health care providers were performed by us and others to help identify the patient experience and the suggested means to provide support and improve quality of life. The people and processes needed to provide a comprehensive and supportive experience are discussed. RESULTS: Patients perceive several crises along the treatment continuum from "shock and the unknown" with the initial diagnosis, "anticipation and anxiety" with every new scan, "defeat and limitations" with disease progression and "terminal expectation" towards the end of life. Their desires include honesty, compassion, hope, communication and support services. Continuous follow-up with them and their caregivers minimizes the fear of abandonment with a nurse-navigator being a key person who provides personalized support. The Neuro-Oncologist and multidisciplinary tumor board drive the standard care, with clinical trials providing additional hope. Process improvements, along with symptom management teams comprised of palliative care professionals, can provide maximal supportive services. CONCLUSIONS: A truly multidisciplinary patient and family centered approach needs to be comprehensive, continuous, structured and responsive. A tumor board, neuro-oncologists and nurse navigators are key elements. Palliative care should be renamed "supportive care” and should be utilized along the care continuum. The authors suggest that patients hope and quality of life is optimized with this approach. SECONDARY CATEGORY: n/a.
SAT0470 Matrix Metalloproteinase-3 (MMP-3) Correlates with Low Bone Mineral Density (BMD) at the Lumbar Spine, but not at the Femoral Neck in Patients with Systematic Lupus Erythematosus (SLE)
Authors: H. Kishimoto, S. Nishiyama, Y. Yoshinaga, T. Aita, K. Ohashi, S. Miyawaki, S. Miyoshi, Y. Yoshihara, M. Toda, M. Tsuno
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> There are few articles show the difference of risk factor of osteoporosis between the lumbar spine and the femoral neck in SLE patients<sup>1–6</sup>. <h3>Objectives</h3> To compare the risk factor of osteoporosis between the lumbar spine and the femoral neck in SLE patients. <h3>Methods</h3> Consecutive 39 cases with SLE (mean age 49.1 years, 38 female, one male) who visited our hospital from Jun. 2012 to Dec. 2013 were studied. BMD was measured with dual-energy X-ray absorptiometry at the lumbar spine and the femoral neck, and correlations between BMD and age, disease duration, age of onset, disease activity (SLEDAI), glucocorticosteroid dose, thyroid function (TSH, freeT4), renal function (serum and urine β2-microglobuline, GFR, cystatin C) and other serum factors (C3, C4, 25-hydroxyvitamin D (25(OH)D), calcium, MMP-3) were examined by multivariate analysis. <h3>Results</h3> According to the WHO criteria, rates of osteoporosis, osteopenia, and normal BMD at the lumbar spine were 38%, 21%, and 41%, and at the femoral neck, 23%, 44%, and 33%, respectively. By stepwise regression, only MMP-3 negatively correlated with BMD at lumbar spine, but did not with BMD at the femoral neck. Although high rate (74%) of 25(OH)D deficiency were found, there was no correlation between BMD and serum level of 25(OH)D. <h3>Conclusions</h3> High prevalence of osteopenia and osteoporosis as well as 25(OH)D were found in patients with SLE. High level of serum MMP-3 may affect on decrease in BMD at lumbar spine, but at the femoral neck in SLE patients. Although the reason is unknown, we have to keep in mind high MMP-3 has possibility the cause of bone fragility at the lumbar spine in SLE patients. <h3>References</h3> García-Carrasco M, et al. Osteoporosis in patients with systemic lupus erythematosus. Isr Med Assoc J. 2009; 11:486-91. Furukawa M, et al. Prevalence of and risk factors for low bone mineral density in Japanese female patients with systemic lupus erythematosus. Rheumatol Int. 2011; 31:365-76. Gilboe IM, et al. Bone mineral density in systemic lupus erythematosus: comparison with rheumatoid arthritis and healthy controls. Ann Rheum Dis 2000; 59: 110-15. Lakshminarayanan S, et al. Factors associated with low bone mineral density in female patients with systemic lupus erythematosus. J Rheumatol 2001; 28: 102-8. Bultink, et al. Prevalence of and risk factors for low bone density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum 2005; 54: 2044-50. Mok CC, et al. Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus. Lupus 2005; 14: 106-12. <h3>Acknowledgements</h3> - <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.2923